Clark, P. J., Santoro, R., Piazzolla, V., Mottola, L., Bacca, D., Dello Iacono, N., … Mangia, A. (2012). Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major treated for chronic hepatitis C. In HEPATOLOGY (Vol. 56, pp. 1028A-1029A). Boston, MA: WILEY-BLACKWELL.

Clark, Paul J., Rosanna Santoro, Valeria Piazzolla, Leonardo Mottola, D. Bacca, N. Dello Iacono, Salvatore Grimaldi, et al. “Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major treated for chronic hepatitis C.” In HEPATOLOGY, 56:1028A-1029A. WILEY-BLACKWELL, 2012.

Clark PJ, Santoro R, Piazzolla V, Mottola L, Bacca D, Dello Iacono N, et al. Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major treated for chronic hepatitis C. In: HEPATOLOGY. WILEY-BLACKWELL; 2012. p. 1028A-1029A.

Clark, Paul J., et al. “Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major treated for chronic hepatitis C.” HEPATOLOGY, vol. 56, WILEY-BLACKWELL, 2012, pp. 1028A-1029A.

Clark PJ, Santoro R, Piazzolla V, Mottola L, Bacca D, Dello Iacono N, Grimaldi S, Quarta A, Urban TJ, Naggie S, Patel K, Thompson AJ, Muir AJ, Mangia A. Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major treated for chronic hepatitis C. HEPATOLOGY. WILEY-BLACKWELL; 2012. p. 1028A-1029A.